» Articles » PMID: 24428878

Pseudomonas Aeruginosa Serotypes in Nosocomial Pneumonia: Prevalence and Clinical Outcomes

Abstract

Introduction: Pseudomonas aeruginosa frequently causes nosocomial pneumonia and is associated with poor outcome. The purpose of this study was to assess the prevalence and clinical outcome of nosocomial pneumonia caused by serotype-specific P. aeruginosa in critically ill patients under appropriate antimicrobial therapy management.

Methods: A retrospective, non-interventional epidemiological multicenter cohort study involving 143 patients with confirmed nosocomial pneumonia caused by P. aeruginosa. Patients were analyzed for a period of 30 days from time of nosocomial pneumonia onset. Fourteen patients fulfilling the same criteria from a phase IIa studyconducted at the same time/centers were included in the prevalence calculations but not in the clinical outcome analysis.

Results: The prevalence of serotypes was: O6 (29%), O11 (23%), O10 (10%), O2 (9%), and O1 (8%). Serotypes with a prevalence of less than 5% were found in 13% of patients, 8% were classified as not typeable. Across all serotypes, 19% mortality, 70% clinical resolution, 11% clinical continuation, and 5% clinical recurrence were recorded. Age and higher APACHE II (Acute Physiology and Chronic Health Evaluation II) were predictive risk factors associated with probability of death and lower clinical resolution for P. aeruginosa nosocomial pneumonia. Mortality tends to be higher with O1 (40%) and lower with O2 (0%); clinical resolution tends to be better with O2 (82%) compared to other serotypes. Persisting pneumonia with O6 and O11 was, respectively, 8% and 21%; clinical resolution with O6 and O11 was, respectively, 75% and 57%.

Conclusions: In P. aeruginosa nosocomial pneumonia, the most prevalent serotypes were O6 and O11. Further studies including larger group sizes are needed to correlate clinical outcome with virulence factors of P. aeruginosa in patients with nosocomial pneumonia caused by various serotypes; and to compare O6 and O11, the two serotypes most frequently encountered in critically ill patients.

Citing Articles

Nosocomial Pneumonia in Georgia: A Study of Extended Spectrum Beta-Lactamase (ESBL)-Producing Versus Non-extended ESBL Gram-Negative Bacterial Profiles.

Mgeladze G, Akhvlediani G, Khetsuriani S, Maisuradze G, Mrelashvili S, Robakidze V Cureus. 2025; 16(12):e75458.

PMID: 39791028 PMC: 11716329. DOI: 10.7759/cureus.75458.


Phylogenetic evaluation and genotypic identification of burn-related Pseudomonas aeruginosa strains isolated from post-burn human infections during hospitalization.

Sanjar F, Millan C, Leung K Pathog Dis. 2024; 82.

PMID: 39496512 PMC: 11556336. DOI: 10.1093/femspd/ftae021.


Genomic Insights into Vietnamese Extended-Spectrum β-Lactamase-9-Producing Extensively Drug-Resistant Isolates Belonging to the High-Risk Clone ST357 Obtained from Bulgarian Intensive Care Unit Patients.

Strateva T, Stratev A, Peykov S Pathogens. 2024; 13(9).

PMID: 39338911 PMC: 11435151. DOI: 10.3390/pathogens13090719.


Unveiling the microevolution of antimicrobial resistance in selected Pseudomonas aeruginosa isolates from Egyptian healthcare settings: A genomic approach.

Salem S, Abdelsalam N, Shata A, Mouftah S, Cobo-Diaz J, Osama D Sci Rep. 2024; 14(1):15500.

PMID: 38969684 PMC: 11226647. DOI: 10.1038/s41598-024-65178-y.


Impact of multidrug resistance on the virulence and fitness of Pseudomonas aeruginosa: a microbiological and clinical perspective.

Sendra E, Fernandez-Munoz A, Zamorano L, Oliver A, Horcajada J, Juan C Infection. 2024; 52(4):1235-1268.

PMID: 38954392 PMC: 11289218. DOI: 10.1007/s15010-024-02313-x.


References
1.
Kurahashi K, Kajikawa O, Sawa T, Ohara M, Gropper M, Frank D . Pathogenesis of septic shock in Pseudomonas aeruginosa pneumonia. J Clin Invest. 1999; 104(6):743-50. PMC: 408437. DOI: 10.1172/JCI7124. View

2.
Rouby J, Martin de Lassale E, Poete P, Nicolas M, Bodin L, Jarlier V . Nosocomial bronchopneumonia in the critically ill. Histologic and bacteriologic aspects. Am Rev Respir Dis. 1992; 146(4):1059-66. DOI: 10.1164/ajrccm/146.4.1059. View

3.
. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005; 171(4):388-416. DOI: 10.1164/rccm.200405-644ST. View

4.
Bert F, Bruneau B, Lambert-Zechovsky N, Branger C . [Epidemiological studies of the susceptibility of Pseudomonas aeruginosa to antibiotics]. Pathol Biol (Paris). 1994; 42(5):491-7. View

5.
Rocchetta H, Burrows L, Lam J . Genetics of O-antigen biosynthesis in Pseudomonas aeruginosa. Microbiol Mol Biol Rev. 1999; 63(3):523-53. PMC: 103745. DOI: 10.1128/MMBR.63.3.523-553.1999. View